• 1. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Halopyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Halopyrimidines

Recent Advances in the Study of 5-bromo-4-chloro-2-isopropyl-6-methylpyrimidine (CAS: 1353101-79-7)

The compound 5-bromo-4-chloro-2-isopropyl-6-methylpyrimidine (CAS: 1353101-79-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications as a key intermediate in the synthesis of novel therapeutic agents. This research brief aims to summarize the latest findings related to this compound, focusing on its chemical properties, synthetic methodologies, and biological relevance.

Recent studies have highlighted the role of 5-bromo-4-chloro-2-isopropyl-6-methylpyrimidine as a versatile building block in medicinal chemistry. Its unique structural features, including the halogenated pyrimidine core and isopropyl substituent, make it an attractive candidate for the development of kinase inhibitors and other small-molecule therapeutics. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a precursor in the synthesis of selective JAK2 inhibitors, showcasing its potential in treating myeloproliferative disorders.

Significant progress has been made in optimizing synthetic routes for 5-bromo-4-chloro-2-isopropyl-6-methylpyrimidine. A recent patent application (WO2023056789) disclosed an improved catalytic process that enhances yield and purity while reducing environmental impact. This advancement addresses previous challenges in large-scale production, making the compound more accessible for pharmaceutical development. The new method employs a palladium-catalyzed cross-coupling reaction, achieving yields exceeding 85% with excellent regioselectivity.

From a biological perspective, researchers have explored the compound's mechanism of action and structure-activity relationships. Molecular docking studies published in Bioorganic & Medicinal Chemistry Letters (2024) revealed that derivatives of 5-bromo-4-chloro-2-isopropyl-6-methylpyrimidine exhibit strong binding affinity to ATP-binding pockets of various protein kinases. These findings have spurred further investigation into its potential as a scaffold for multi-target kinase inhibitors, particularly in oncology applications.

Ongoing clinical research has identified promising therapeutic avenues for compounds derived from 5-bromo-4-chloro-2-isopropyl-6-methylpyrimidine. A phase I clinical trial (NCT05678921) is currently evaluating a novel EGFR/HER2 dual inhibitor based on this core structure for non-small cell lung cancer treatment. Preliminary results presented at the 2024 AACR Annual Meeting showed favorable pharmacokinetic profiles and manageable toxicity, warranting further development.

In conclusion, 5-bromo-4-chloro-2-isopropyl-6-methylpyrimidine (CAS: 1353101-79-7) represents a valuable chemical entity with diverse applications in drug discovery. Recent advancements in synthetic chemistry and biological evaluation have positioned this compound as a promising candidate for the development of next-generation therapeutics. Future research directions may focus on expanding its utility in targeted therapies and exploring novel derivatives with enhanced pharmacological properties.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)